On 12 April 2011, the second EP Interest Group on Complementary & Alternative Medicine (CAM) convened at the European Parliament to discuss the potential benefits that CAM can contribute to the European Innovation Partnership on Healthy and Active Ageing.
The meeting, chaired by Marian Harkin MEP (ALDE, Ireland) brought together CAM doctors and practitioners as well as representatives of the European Commission and other interested MEPs. Ms Harkin explained the purpose of the meeting, a discussion of CAM’s potential for achieving the headline target of the EIP (= adding 2 healthy life years by 2020) through its focus on health promotion and sustainability. Given the proliferation of chronical diseases and urgent need to prevent and manage them, alternative models must be considered given the costs that health systems will have to bear.
Jorge Pinto Antunes of DG SANCO’s strategy and analysis unit gave the same presentation of the European Innovation Partnership on Healthy and Active Ageing that he provided at a recent MEP Heart Group meeting (for a description please see here. He confirmed that the EIP’s focus was really on partnerships, and the Commission was seeking views from the CAM community as well as from patients, the health workforce, and industry. There is a chance for CAM to contribute to the EIP managing the health of people (e.g. through its focus on self-care and prevention) and that of systems (e.g. palliative care, home care).
EPHA member Ton Nicolai of the European Committee for Homeopathy then presented the essential differences in the underlying paradigms of the Western biomedical model and CAM. In spite of its many achievements, the former is reactive and does not restore patients to health and autonomy, whereas the CAM model is holistic and focuses on an individual’s resources to create health, i.e. it is based on the concept of salutogenesis. The limits of conventional medicine are also evident when taking into account problems such as adverse drug reactions, polypharmacy and the high costs involved in many medicines. Mr. Nicolai said that the evidence base of CAM is also growing steadily. As for cost effectiveness, a recent Dutch study amongst 150,000 individuals ound that they incurred substantially lower healthcare costs and mortality rates if their GP had received CAM training. There are many arguments for having integrated health centres and multidisciplinary teams, not least the fact that CAM patients’ satisfaction rates are high.
Finally, Seamus Connolly of the European Shiatsu Federation, also a member of EPHA, stressed that Europe needed provision of healthcare from cradle to grave. There was an entire cohort of healthcare workers currently operating outside of the formal system who could act as guides to citizens to stimulate lifestyle changes based on CAM principles. A wider health promotion approach could even help older people to manage their health. He deplored the following obstacles:
– the bulk of CAM treatments are currently outside of the health system hence it is for pay: only those who can afford it can access it
– a ”regime of tolerance” exists for many CAM practitioners who are not legally entitled to practise
– EU projects like the EIP on Healthy & Active Ageing should include CAM
In summary, Mr. Connolly said that a paradigm shift is needed in order for CAM to play a bigger role in the provision of healthcare and overcome the problems that users and practitioners currently experience. Ms Harkin MEP added that there were many different notions of CAM in Europe which would need to be taken into account when it comes to improving access.
Finally, Harsha Gramminger, Vice-President of EPHA member the Association of Natural Medicine in Europe and Director of the European Ayurveda Association underlined the fact that the Traditional Herbal Medicinal Products Directive (THMPD) that will come into effect in April 2011 will create major problems for the availability of CAM products based on herbal and other ingredients (e.g. minerals, vitamins, products of animal origin, etc.) as is the case in ayurveda and traditional Chinese medicine. A future revision of the Directive would ensure that such products can also support healthy and active ageing.
—-
For more information:
Pilot European Innovation Partnership on Healthy and Active Ageing
Related articles:
– [->art4486]
– [->art4004]
– [->art4198]
